StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN) stock

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$957.76+5.36 (+0.56%)

Close on Nov 17, 2026Market cap $99.08BP/E 21.2Yield –

Regeneron Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Regeneron Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was $4.86B, up 31.9% year over year. For fiscal 2025 it was $3.58B, down 10.3% from the year before. Over ten years it grew 11.1% a year on average. The highest annual figure on record is $8.95B in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.58B-10.3%
FY2024Dec 31, 2024$3.99B-1.4%
FY2023Dec 31, 2023$4.05B-14.6%
FY2022Dec 31, 2022$4.74B-47.0%
FY2021Dec 31, 2021$8.95B+150.1%
FY2020Dec 31, 2020$3.58B+61.9%
FY2019Dec 31, 2019$2.21B-12.8%
FY2018Dec 31, 2018$2.53B+21.9%
FY2017Dec 31, 2017$2.08B+56.3%
FY2016Dec 31, 2016$1.33B+6.3%
FY2015Dec 31, 2015$1.25B+51.9%
FY2014Dec 31, 2014$823.92M+10.9%
FY2013Dec 31, 2013$743.05M+62.3%
FY2012Dec 31, 2012$457.71M–
FY2011Dec 31, 2011-$205.16M–
FY2010Dec 31, 2010-$97.47M–
FY2009Dec 31, 2009-$74.10M–
FY2008Dec 31, 2008-$86.25M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.05B+99.5%
Q2 FY2026Jun 30, 2026$1.29B+19.8%
Q1 FY2026Mar 31, 2026$642.90M+8.7%
Q4 FY2025Dec 31, 2025$879.90M-11.1%
Q3 FY2025Sep 30, 2025$1.03B-12.9%
Q2 FY2025Jun 30, 2025$1.08B+0.9%
Q1 FY2025Mar 31, 2025$591.70M-21.3%
Q4 FY2024Dec 31, 2024$990.20M+1.8%
Q3 FY2024Sep 30, 2024$1.18B+6.2%
Q2 FY2024Jun 30, 2024$1.07B+5.2%
Q1 FY2024Mar 31, 2024$751.40M-20.6%
Q4 FY2023Dec 31, 2023$972.90M-15.2%
Q3 FY2023Sep 30, 2023$1.11B-9.2%
Q2 FY2023Jun 30, 2023$1.02B-8.4%
Q1 FY2023Mar 31, 2023$946.70M-24.8%
Q4 FY2022Dec 31, 2022$1.15B-56.6%
Q3 FY2022Sep 30, 2022$1.22B-33.8%
Q2 FY2022Jun 30, 2022$1.11B-66.8%
Q1 FY2022Mar 31, 2022$1.26B+13.1%
Q4 FY2021Dec 31, 2021$2.64B+126.2%
Q3 FY2021Sep 30, 2021$1.85B+75.4%
Q2 FY2021Jun 30, 2021$3.35B+409.9%
Q1 FY2021Mar 31, 2021$1.11B+58.9%
Q4 FY2020Dec 31, 2020$1.17B+72.7%
Q3 FY2020Sep 30, 2020$1.05B+42.6%
Q2 FY2020Jun 30, 2020$656.40M+108.0%
Q1 FY2020Mar 31, 2020$700.10M+45.9%
Q4 FY2019Dec 31, 2019$675.70M-5.9%
Q3 FY2019Sep 30, 2019$738.50M+17.8%
Q2 FY2019Jun 30, 2019$315.60M-49.3%
Q1 FY2019Mar 31, 2019$480.00M-15.4%
Q4 FY2018Dec 31, 2018$718.10M+33.3%
Q3 FY2018Sep 30, 2018$626.90M+12.0%
Q2 FY2018Jun 30, 2018$622.20M+13.1%
Q1 FY2018Mar 31, 2018$567.20M+31.7%
Q4 FY2017Dec 31, 2017$538.82M+55.3%
Q3 FY2017Sep 30, 2017$559.93M–
Q2 FY2017Jun 30, 2017$550.31M–
Q1 FY2017Mar 31, 2017$430.54M–
Q4 FY2016Dec 31, 2016$346.96M–

More Regeneron Pharmaceuticals figures

See a number that looks wrong?